Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T4KG
|
|||
| Former ID |
DIB006125
|
|||
| Drug Name |
F-8-IL-10 fusion protein
|
|||
| Synonyms |
Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen
Click to Show/Hide
|
|||
| Indication | Endometriosis [ICD-11: GA10; ICD-10: N80, N80.9; ICD-9: 617] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [2] | ||
| Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 1 | [2] | ||
| Company |
Pfizer
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02270632) A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 Dekavil) in Patients With Active RA Receiving MTX. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.